Technical Analysis for AGRX - Agile Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.56 | 3.13% | 0.02 |
AGRX closed up 3.13 percent on Monday, March 18, 2024, on 47 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 20
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 3.13% | |
New 52 Week Closing Low | Bearish | 3.13% | |
Lower Bollinger Band Walk | Weakness | 3.13% | |
New 52 Week Low | Weakness | 3.13% | |
Wide Bands | Range Expansion | 3.13% |
Alert | Time |
---|---|
Possible Inside Day | about 14 hours ago |
60 Minute Opening Range Breakout | about 17 hours ago |
Up 5% | about 17 hours ago |
Down 2 % | about 18 hours ago |
2x Volume Pace | about 18 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/20/2024
Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Clinical Development Alcohol Organic Compounds Estrogen Transdermal Estranes Hormonal Contraception Medroxyprogesterone Acetate
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Clinical Development Alcohol Organic Compounds Estrogen Transdermal Estranes Hormonal Contraception Medroxyprogesterone Acetate
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 14.5 |
52 Week Low | 0.5068 |
Average Volume | 752,877 |
200-Day Moving Average | 2.08 |
50-Day Moving Average | 1.20 |
20-Day Moving Average | 0.79 |
10-Day Moving Average | 0.70 |
Average True Range | 0.10 |
RSI (14) | 20.00 |
ADX | 30.17 |
+DI | 16.17 |
-DI | 33.54 |
Chandelier Exit (Long, 3 ATRs) | 1.02 |
Chandelier Exit (Short, 3 ATRs) | 0.80 |
Upper Bollinger Bands | 1.04 |
Lower Bollinger Band | 0.53 |
Percent B (%b) | 0.06 |
BandWidth | 64.82 |
MACD Line | -0.18 |
MACD Signal Line | -0.18 |
MACD Histogram | -0.001 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.63 | ||||
Resistance 3 (R3) | 0.63 | 0.61 | 0.62 | ||
Resistance 2 (R2) | 0.61 | 0.59 | 0.61 | 0.62 | |
Resistance 1 (R1) | 0.58 | 0.58 | 0.57 | 0.58 | 0.61 |
Pivot Point | 0.56 | 0.56 | 0.55 | 0.56 | 0.56 |
Support 1 (S1) | 0.53 | 0.54 | 0.52 | 0.54 | 0.51 |
Support 2 (S2) | 0.51 | 0.53 | 0.51 | 0.50 | |
Support 3 (S3) | 0.48 | 0.51 | 0.50 | ||
Support 4 (S4) | 0.49 |